First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study

Hisao Imai,Takashi Kijima,Koichi Azuma,Kazuma Kishi,Haruhiro Saito,Teppei Yamaguchi,Junko Tanizaki,Yasuto Yoneshima,Kohei Fujita,Satoshi Watanabe,Satoru Kitazono,Tatsuro Fukuhara,Osamu Hataji,Yukihiro Toi,Hideaki Mizutani,Yusuke Hamakawa,Makoto Maemondo,Tomoyuki Ohsugi,Keisuke Suzuki,Hidehito Horinouchi,Yuichiro Ohe

DOI: https://doi.org/10.1093/jjco/hyad195

IF: 2.925

2024-01-25

Japanese Journal of Clinical Oncology

Abstract:Abstract Objective As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however, data on Japanese patients are limited. Methods LIGHT-NING was a multicenter, observational study and retrospectively collected data. In this interim analysis, we analyzed patients who received combination immunotherapy between 27 November 2020 and 31 August 2021 for the treatment status, safety objectives (treatment-related adverse events and immune-related adverse events incidences), and effectiveness objectives (objective response rate and progression-free survival) to determine the characteristics and early safety information. Results We analyzed 353 patients, with a median follow-up of 7.1 (interquartile range, 5.0–9.7) months. Overall, 60.1 and 39.9% received nivolumab plus ipilimumab with and without chemotherapy, respectively. In these cohorts, the median age was 67 and 72 years; 10.8 and 35.5% were aged ≥75 years; 80.2 and 79.4% were male; 5.2 and 13.5% had a performance score ≥ 2; 32.1 and 27.0% developed grade 3–4 immune-related adverse events; treatment-related deaths were observed in 6 (2.8%) and 5 (3.5%) patients, respectively. Grade 3–4 immune-related adverse event incidence was the highest within the first month of treatment in both cohorts, although the immune-related adverse event risk persisted throughout. No new safety signals were observed at this interim analysis. The median progression-free survival was 6.0 (95% confidence interval, 5.2–7.6) and 5.8 (4.3–7.0) months in nivolumab plus ipilimumab with and without chemotherapy cohorts, respectively. Conclusions LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the safety and efficacy of nivolumab combined with ipilimumab, with or without chemotherapy as first - line treatment, in untreated stage IV or recurrent non - small - cell lung cancer (NSCLC) patients in the real - world environment in Japan. Specifically, the study aims to:

1. **Describe the treatment status**: Understand the treatment patterns and duration of patients receiving this combination therapy.
2. **Evaluate safety**:
- Analyze the incidence of treatment - related adverse events (TRAEs), especially grade 3 - 4 immune - related adverse events (irAEs).
- Evaluate the occurrence of TRAEs and irAEs that lead to treatment interruption.
- Observe the situation of treatment - related deaths.
3. **Evaluate efficacy**:
- Calculate the objective response rate (ORR), disease control rate (DCR) and progression - free survival (PFS).
- Analyze the differences in efficacy in different subgroups (such as age, ECOG performance status score, histological type, etc.).

Through these evaluations, the study hopes to provide valuable insights for the use of this combination therapy in Japanese clinical practice and verify its safety and efficacy in the real - world environment.

### Key points summary
- **Research background**: Although nivolumab combined with ipilimumab has been proven to be effective for metastatic NSCLC, the data in Japanese patients are limited.
- **Research design**: This is a multi - center, observational study (LIGHTNING), which retrospectively collected patient data from November 27, 2020 to August 31, 2021.
- **Main findings**:
- **Safety**: The incidence of grade 3 - 4 irAEs was the highest in the first month of treatment, but the risk persisted throughout the observation period.
- **Efficacy**: The median progression - free survival (mPFS) was 6.0 months (in the combination chemotherapy group) and 5.8 months (in the non - combination chemotherapy group), respectively. The objective response rate (ORR) was 39.6% (in the combination chemotherapy group) and 37.0% (in the non - combination chemotherapy group), respectively.

These results provide important reference information for the use of this combination therapy in Japanese NSCLC patients.